SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-22-004976
Filing Date
2022-06-09
Accepted
2022-06-09 16:58:33
Documents
2
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6294
2 POA UPDATED JUNE 2022 poa_mrogers2022.txt EX-24 3482
  Complete submission text file 0001562180-22-004976.txt   11132
Mailing Address C/O KERYX BIOPHARMACEUTICALS INC ONE MARINA PARK DRIVE BOSTON MA 02210
Business Address
ROGERS MICHAEL W (Reporting) CIK: 0001244159 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36352 | Film No.: 221006647

Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Issuer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations